Jefferies Financial Group Inc. Acquires Shares of 6,697 United Therapeutics Corporation $UTHR

Jefferies Financial Group Inc. bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 6,697 shares of the biotechnology company’s stock, valued at approximately $3,629,000.

Several other institutional investors and hedge funds also recently made changes to their positions in UTHR. Torren Management LLC acquired a new position in United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management grew its position in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the last quarter. Fiduciary Financial Advisors bought a new position in United Therapeutics in the 2nd quarter valued at $30,000. WealthCollab LLC boosted its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Finally, Rakuten Securities Inc. increased its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Down 2.4%

United Therapeutics stock opened at $515.46 on Friday. The company has a market cap of $22.11 billion, a P/E ratio of 18.44, a price-to-earnings-growth ratio of 1.79 and a beta of 0.59. United Therapeutics Corporation has a 1-year low of $303.08 and a 1-year high of $609.35. The company has a fifty day simple moving average of $530.46 and a 200 day simple moving average of $538.70.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the previous year, the firm posted $6.41 EPS. On average, equities research analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current year.

Analyst Upgrades and Downgrades

UTHR has been the subject of several research reports. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Bank of America cut their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Finally, Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a report on Thursday, August 6th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $646.00.

Insider Transactions at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $541.39, for a total value of $5,143,205.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $21,933,333.07. This trade represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,311,581.28. This trade represents a 34.63% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 424,075 shares of company stock valued at $227,336,485. Insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.